GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
Looking forward to meeting GAiT members at the annual @NYSCF meeting http://www.nyscf.org/events
The iPSC Quality Assessment Round Data Manuscript has been sent to all Authors for final review. Please check your inboxes. We shall submit the manuscript after responding to final questions and comments.
The iPSC Quality Assessment Round Manuscript is to be circulated to all authors tomorrow for final review & edit before submission. Authors will have two weeks to review. Well done to all Organizers and Participants for getting this far, especially with all the COVID disruption.
Excellent line up for this year's virtual @nyscf
conference hosted by GAiT Director @SusanNYSCF
The NYSCF Conference - New York Stem Cell Foundation
The NYSCF Conference is the leading scientific meeting on translational stem cell research. It...
Did you know? GAiT's Industry Liaison Committee is co-chaired by @CiRA_F_J pediatric oncologist Dr. Noriko Shimasaki and @CCRM_ca President/CEO and GAiT Director Dr @MichaelMay5. The Committee focuses on accelerating iPSC therapies to the clinic.
GAiT members are hoping to see each other in person at Phacilitate Advanced Therapies Week in Miami. Register at https://www.advancedtherapiesweek.com/welcome
How registries and manufacturers/developers can work together effectively to accelerate cell therapies was discussed at the WMDA CGT webinar this morning. Material procurement is currently a key issue for manufacturers and this includes suitable donor material.
GAiT is sad to hear of the passing of Dr Wen Bo Wang. Our deepest condolences to her family and friends. May She rest in peace.
Wen Bo Wang Obituary - Oceanside, CA
Celebrate the life of Wen Bo Wang, leave a kind word or memory and get funeral service information care of Ete...
iPSC translation e-book developed by @regenmed and @biotechne https://resources.bio-techne.com/bio-techne-assets/images/literature/RMN_Bio-Techne_iPSCs_eBook.pdf?utm_medium=paidsocial&utm_source=linkedin&utm_campaign=BT-08-2021-CGTBU-iPSC-eBook_B